Research
Nafarelin — living evidence map
The Atlas page holds the claims; this is how its evidence evolved.
Summary
Nafarelin is a GnRH agonist given as a nasal spray; in a six-month double-blind trial in 213 women with endometriosis it reduced disease extent at laparoscopy as much as oral danazol, with hot flashes rather than the adverse lipid changes seen with danazol. · pmid:2963213
Identity
PubChem CID 25077405: Nafarelin, C66H83N17O13, 1322.5 g/mol. · pubchem:25077405
CAS registry number 76932-56-4. · pubchem:25077405
Where the evidence actually sits
Proportion of the 1 claim about Nafarelin standing at each tier. Community volume is shown on the Consensus tab beside this and is never averaged into it.
Living evidence history
1 resolved citation, oldest to newest, coloured by tier. Retractions and contradictions land here as they are recorded.
Structure
No structure representation on record. PepJunkie draws only what an authoritative record supplies; for a peptide that is the residue sequence, and none has been curated for Nafarelin yet.
Dose evidence, rung by rung
A studied human dose exists on file. Open the rung: the dose is the paper's, in its context, never PepJunkie's.
- Approved-label dose · a resolved regulatory document names a labelled dose
nothing resolved on this rung
- Studied human doses · resolved human studies at the established tier
- Administration of nasal nafarelin as compared with oral danazol for endometriosis. A multicenter double-blind comparative clinical trial. · pmid 2963213 · 1988
- Observational evidence · resolved human data at the emerging tier: thin, or contested
nothing resolved on this rung
- Community-reported protocols · protocol propositions from distinct members, counted once per human
nothing resolved on this rung
- Preclinical evidence · resolved animal, cell or mechanistic work
nothing resolved on this rung
1 resolved citation, 0 unresolved (an unresolved citation lends nothing). Community volume is its own rung and is never averaged into the evidence rungs.